<--- Back to Details
First PageDocument Content
Clinical medicine / Medicine / Antineoplastic drugs / Breakthrough therapy / Pharmacology / Bristol-Myers Squibb / Monoclonal antibodies / Immune system / Programmed cell death protein 1 / Nivolumab / Pharmac / Pembrolizumab
Date: 2016-05-25 01:37:50
Clinical medicine
Medicine
Antineoplastic drugs
Breakthrough therapy
Pharmacology
Bristol-Myers Squibb
Monoclonal antibodies
Immune system
Programmed cell death protein 1
Nivolumab
Pharmac
Pembrolizumab

24 MayDanae Staples-Moon Therapeutic Group Manager PHARMAC PO Box

Add to Reading List

Source URL: www.nzma.org.nz

Download Document from Source Website

File Size: 204,92 KB

Share Document on Facebook

Similar Documents

PDF Document

DocID: 1xvUb - View Document

PDF Document

DocID: 1xc8R - View Document

Institute of Pharmacology www.pki.unibe.ch Introduction Prof. Dr. Dr. Stephan von Gunten MD PhD MME

DocID: 1vqsj - View Document

Jansone et al.: Intrinsic Activity, 2017; 5 (Suppl.2):A1.6 doi:IA.5.S2-A1.6 published online: 16 October 2017 2nd International Conference in Pharmacology: From Cellular Processes to Drug Targets Rīga, Latvia

DocID: 1vlJU - View Document

Human cells Notable for research in: -Medecine: Diseases and cancers -Cell Biology -Pharmacology

DocID: 1vk1K - View Document